Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

The steady approval of new biosimilars in recent years provides additional safe, effective, and cost-effective options for ...

By Patrick Wingrove and Puyaan Singh (Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts ...

Key Takeaways Federal regulators will no longer require costly clinical trials for most biosimilars, speeding up approvalThe ...

AbbVie raised its earnings guidance for 2025 and added to its quarterly dividend after another strong quarter of revenue ...

This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...

The affordability of health insurance is severely strained right now, with premium increases in the double digits being passed along to many Michiganders for the past several years in a row. Tackling ...

A judge on Saturday temporarily blocked the Trump administration from sending underage migrants to adult detention centers once they turn 18. U.S. District Judge Rudolph Contreras said the new policy ...

Separately, in the administration’s first 200 days, only two of 98 Senate-confirmed appointees to the most senior jobs in government were Black. Separately, in the administration’s first 200 days, ...